Markets

Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor, For Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Oct 2, 2026 · 03:09 PM ET· updated 1h ago

Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton

Why It Matters

Eli Lilly got approval to use its cancer medicine Jaypirca for more patients. When a company wins FDA approval for new uses, it can sell more medicine and grow revenue.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LLY1,142.50

-7.35 (-0.64%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.